Author

Takuya Okagaki

Observed names: Okagaki, Takuya, TAKUYA OKAGAKI

Institutions: UCB Pharma (Japan), UCB Pharma (Belgium)

Observed institutions: UCB Pharma (Japan), Tanabe Pharma Corporation (Japan), UCB Pharma (Belgium)

OpenAlex ID: A5084864633

Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer

1998 · Masaaki Sugimoto, Takuya Okagaki, et al. · International Journal of Pharmaceutics · 186

Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration

2014 · Nathalie Toublanc, Takuya Okagaki, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 6

Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil

2024 · Hugues Chanteux, Merran MacPherson, et al. · Expert Opinion on Drug Metabolism & Toxicology · 2

Potentiation of antitumor effect of aclarubicin on rat hepatoma model by hepatic arterially administered oily dosage forms.

1988 · TAKUYA OKAGAKI, HIROSHI YOSHIKAWA, et al. · Chemical and Pharmaceutical Bulletin · 1

The pharmacologic and pharmacokinetic properties of certolizumab pegol

2015 · Takuya Okagaki · The Japanese Society for the Study of Xenobiotics

A simulation work for comparison of ease-of-use between NONMEM and SAS NLMIXED procedure : first order and adaptive gaussian quadrature methods

2005 · Takuya Okagaki, Chikao Ishikawa, et al. · The Keio Journal of Medicine

Works count: 7

Citation count: 195

H-index: 2

I10-index: 1